other material
confidence high
sentiment positive
materiality 0.60
Benitec reports positive interim data from BB-301 Phase 1b/2a: swallowing improvements in two OPMD subjects
Benitec Biopharma Inc.
- Subject 1 at Day 270: 35% SSQ Total Score reduction, 33% VFSS TPR reduction for thin liquids.
- Subject 2 at Day 180: 89% SSQ Total Score reduction (score 82, clinically normal swallowing), 92% reduction in low-volume sequential swallows.
- No Significant Adverse Events observed with low-dose BB-301 (1.2e13 vg/subject).
- Third subject to be dosed this month; higher-dose cohorts enrollment expected in 2025.